A less-frequent, fixed dose regimen of Imfinzi (durvalumab) has been approved in the European Union and U.K. to treat adults with locally advanced, inoperable non-small cell lung cancer (NSCLC), announced the therapy’s developer, AstraZeneca. This new dosing option, which will reduce the need for medical appointments, will be available to NSCLC patients weighing more than 30 kg (about 66 pounds), whose disease has not progressed following platinum-based chemoradiation therapy, and whose tumors have at least…
You must be logged in to read/download the full post.
The post Less-frequent Dosing of Imfinzi Approved in Europe for Advanced Lung Cancer appeared first on BioNewsFeeds.